Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloprost plus eptifibatide versus low-molecular-weight heparin in severe pneumonia with severe sepsis
2011-002254-31Phase 2Terminated
- Sponsor
- Rigshospitalet
- Start
- Jun 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iloprost and eptifibatide in pneumonia, sepsis, septic shock and 1 more (2 arms), sponsored by Rigshospitalet. Primary endpoint: Change in platelet count from baseline to 72 hours post treatment. Started Jun 2011; status: terminated.
02
Drugs
iloprosteptifibatide
03
Conditions
pneumoniasepsisseptic shockbacterial disease
Beyond the preview
Go deeper on 2011-002254-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002254-31.